Drug Profile

Anti CD-137 monoclonal antibody - AstraZeneca

Latest Information Update: 28 May 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator MedImmune
Developer AstraZeneca
Class Antineoplastics; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 May 2022 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
17 Apr 2018 Preclinical trials in Cancer in USA (Parenteral) (before April 2018)
17 Apr 2018 Pharmacodynamics data from a preclinical study in Cancer presented at the 109^th Annual Meeting of the American Association for Cancer Research (AACR-2018)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com